person · Reporting owner

Goldberg Mark Alan

Disclosed activity across 6 companies

Tapewire entity: 77330
SEC CIK: 0001532475

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aceragen, Inc.IDRA · Entity 110652	Director	June 23, 2022	June 27, 2022
CRESCENT BIOPHARMA, INC.GLYC · Entity 5255	Director	May 01, 2024	May 01, 2024
aTYR PHARMA INCLIFE · Entity 7233	Director	May 09, 2017	May 11, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aceragen, Inc.

Report date June 23, 2022 · Filed June 27, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-06-23	Direct	26,000	Reported balance After 2022-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-23 · Grant · Acquired 26,000 · Balance 26,000 F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.

F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.

CRESCENT BIOPHARMA, INC.

Report date May 01, 2024 · Filed May 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30	Direct	40,000	Reported balance After 2024-05-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

aTYR PHARMA INC

Report date May 09, 2017 · Filed May 11, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2027-05-09	Direct	20,000	Reported balance After 2017-05-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-09 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-15 transaction · row 1 1 source row Row 1 · 2020-01-15 · Other · Disposed 1,500 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.91 · Expires 2028-01-01	Direct	Reported balance After 2020-01-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-15 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.00 · Expires 2028-01-18	Direct	Reported balance After 2020-01-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-15 · Disposition to issuer · Disposed 4,500 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08	Direct	Reported balance After 2020-01-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06	Direct	Reported balance After 2020-01-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-07-17 · Disposition to issuer · Disposed 3,902 · Balance 18,254 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 18,254 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.02	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 10,909 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.79	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 7,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.77	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 4,875 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.24	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.13	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.64	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

ImmunoGen, Inc.

Report date February 12, 2024 · Filed February 12, 2024

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-12 transaction · row 1 1 source row Row 1 · 2024-02-12 · Disposition to issuer · Disposed 60,720 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-12 · Disposition to issuer · Disposed 160,350 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2024-11-11	Direct	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.07 · Expires 2025-11-10	Direct	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2026-12-09	Direct	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-06-13	Direct	Reported balance After 2024-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-20	Direct	Reported balance After 2024-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2030-06-17	Direct	Reported balance After 2024-02-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16	Direct	Reported balance After 2024-02-12 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15	Direct	Reported balance After 2024-02-12 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14	Direct	Reported balance After 2024-02-12 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 18, 2022 Filed May 20, 2022 20:08 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001209191-22-030977 · doc4.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:11 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,151	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-22-002534 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,274 Underlying: Common Stock · 3,151 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 31, 2022 Filed Apr 20, 2022 17:38 UTC Amendment	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,545	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-22-002691 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,668 Underlying: Common Stock · 3,545 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F4 · shares: Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F4 · derivative.underlying_shares: Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction. F4 · balance_after: Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction. Read SEC document
March 03, 2022 Filed Mar 7, 2022 16:05 UTC	Blueprint Medicines Corp BPMC · Entity 77326	PurchaseCommon Stock	5,000	$59.98	$299,900.00	Disclosure SEC source: 0001415889-22-002653 · form4-03072022_040307.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,812 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $59.86 to $60.11 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 31, 2021 Filed Jan 4, 2022 16:02 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,819	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-22-000100 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,123 Underlying: Common Stock · 1,819 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2021 Filed Oct 1, 2021 16:14 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,380	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-009041 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,304 Underlying: Common Stock · 2,380 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 30, 2021 Filed Jul 2, 2021 16:22 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,048	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-007319 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,924 Underlying: Common Stock · 2,048 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 16, 2021 Filed Jun 17, 2021 16:23 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	44,000	$6.77 Strike: $6.77	$297,880.00	Disclosure SEC source: 0001179110-21-006817 · edgar.xml · derivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2031-06-16 F4 · derivative.exercise_date: Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 16, 2021 Filed Jun 17, 2021 16:23 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	15,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-006817 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,876 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:06 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0001415889-21-002918 · form4-06102021_050633.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-08 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2021 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on June 8, 2022 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document
June 02, 2021 Filed Jun 4, 2021 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $87.13	$0.00	Disclosure SEC source: 0001179110-21-006420 · edgar.xml · derivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-06-02 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Read SEC document
June 02, 2021 Filed Jun 4, 2021 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001179110-21-006420 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,812 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 18, 2021 Filed May 28, 2021 00:51 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001209191-21-036378 · doc4.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 18, 2021 Filed May 28, 2021 00:51 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantCommon Stock	5,250	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036378 · doc4.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document
April 01, 2021 Filed Apr 5, 2021 16:30 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	10,511	$1.32	$13,874.52	Disclosure SEC source: 0001415889-21-001878 · form4-04052021_040417.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,610 F1 · shares: This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document
March 31, 2021 Filed Apr 2, 2021 13:02 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,666	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-004072 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,876 Underlying: Common Stock · 1,666 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
January 04, 2021 Filed Jan 6, 2021 16:38 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	3,452	$4.02	$13,877.04	Disclosure SEC source: 0001179110-21-000330 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,099 F1 · shares: This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document
December 31, 2020 Filed Jan 4, 2021 10:46 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,093	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-000026 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,210 Underlying: Common Stock · 2,093 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
December 24, 2020 Filed Dec 28, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,455	$0.00 Strike: $28.15	$0.00	Disclosure SEC source: 0001179110-20-012241 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,455 shares Expires 2025-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on June 25, 2015 and is fully vested as of the date hereof. Read SEC document
December 24, 2020 Filed Dec 28, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,455	$125.00	$681,875.00	Disclosure SEC source: 0001179110-20-012241 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 24, 2020 Filed Dec 28, 2020 16:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,455	$28.15	$153,558.25	Disclosure SEC source: 0001179110-20-012241 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 18, 2020 Filed Dec 22, 2020 16:14 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,454	$0.00 Strike: $28.15	$0.00	Disclosure SEC source: 0001179110-20-012178 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,455 Underlying: Common Stock · 5,454 shares Expires 2025-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on June 25, 2015 and is fully vested as of the date hereof. Read SEC document
December 18, 2020 Filed Dec 22, 2020 16:14 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,454	$120.00	$654,480.00	Disclosure SEC source: 0001179110-20-012178 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 18, 2020 Filed Dec 22, 2020 16:14 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,454	$28.15	$153,530.10	Disclosure SEC source: 0001179110-20-012178 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 11, 2020 Filed Dec 15, 2020 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,455	$0.00 Strike: $28.15	$0.00	Disclosure SEC source: 0001179110-20-011906 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,909 Underlying: Common Stock · 5,455 shares Expires 2025-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on June 25, 2015 and is fully vested as of the date hereof. Read SEC document
December 11, 2020 Filed Dec 15, 2020 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,455	$115.00	$627,325.00	Disclosure SEC source: 0001179110-20-011906 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 11, 2020 Filed Dec 15, 2020 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,455	$28.15	$153,558.25	Disclosure SEC source: 0001179110-20-011906 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 01, 2020 Filed Dec 3, 2020 16:10 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,454	$0.00 Strike: $28.15	$0.00	Disclosure SEC source: 0001179110-20-011608 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,364 Underlying: Common Stock · 5,454 shares Expires 2025-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on June 25, 2015 and is fully vested as of the date hereof. Read SEC document
December 01, 2020 Filed Dec 3, 2020 16:10 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,454	$110.00	$599,940.00	Disclosure SEC source: 0001179110-20-011608 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
December 01, 2020 Filed Dec 3, 2020 16:10 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,454	$28.15	$153,530.10	Disclosure SEC source: 0001179110-20-011608 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 19, 2020 Filed Oct 21, 2020 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,455	$0.00 Strike: $19.53	$0.00	Disclosure SEC source: 0001179110-20-010626 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,455 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on June 23, 2016 and is fully vested as of the date hereof. Read SEC document
October 19, 2020 Filed Oct 21, 2020 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,455	$105.00	$572,775.00	Disclosure SEC source: 0001179110-20-010626 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 19, 2020 Filed Oct 21, 2020 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,455	$19.53	$106,536.15	Disclosure SEC source: 0001179110-20-010626 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,454	$0.00 Strike: $19.53	$0.00	Disclosure SEC source: 0001179110-20-010368 · edgar.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,455 Underlying: Common Stock · 5,454 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: This option was granted on June 23, 2016 and is fully vested as of the date hereof. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	5,454	$100.00	$545,400.00	Disclosure SEC source: 0001179110-20-010368 · edgar.xml · nonDerivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 07, 2020 Filed Oct 9, 2020 16:04 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,454	$19.53	$106,516.62	Disclosure SEC source: 0001179110-20-010368 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:06 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	6,166	$2.25	$13,873.50	Disclosure SEC source: 0001179110-20-010221 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,647 F1 · shares: This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document
September 30, 2020 Filed Oct 1, 2020 14:39 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-010030 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,117 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:58 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	7,751	$1.79	$13,874.29	Disclosure SEC source: 0001179110-20-008006 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,481 F1 · shares: This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document
June 30, 2020 Filed Jul 2, 2020 08:34 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,934	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-007815 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,367 Underlying: Common Stock · 2,934 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 24, 2020 Filed Jun 26, 2020 16:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $76.24	$0.00	Disclosure SEC source: 0001179110-20-007796 · edgar.xml · derivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-06-24 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Read SEC document
June 24, 2020 Filed Jun 26, 2020 16:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007796 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 19, 2020 Filed Jun 23, 2020 16:11 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007716 · edgar.xml · derivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. F2 · derivative.expiration_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. Read SEC document
June 19, 2020 Filed Jun 23, 2020 16:11 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,312	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-007716 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:09 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	50,000	$4.56 Strike: $4.56	$228,000.00	Disclosure SEC source: 0001179110-20-007533 · edgar.xml · derivative · entry 2 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 F4 · derivative.exercise_date: Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:09 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	17,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-007533 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,433 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 22, 2020 Filed May 27, 2020 20:28 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001209191-20-032302 · doc4.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 12, 2020 Filed May 19, 2020 19:07 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Option (Right to Buy) · Derivative	11,500	$0.00 Strike: $1.97	$0.00	Disclosure SEC source: 0001179110-20-006348 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2030-05-12 F1 · security: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2020 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2 · derivative.exercise_date: The options vest in full and become immediately exercisable on May 12, 2021 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:19 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	10,730	$1.28	$13,734.40	Disclosure SEC source: 0001179110-20-004665 · edgar.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,730 F1 · shares: This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees. Read SEC document
March 31, 2020 Filed Apr 2, 2020 07:51 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,958	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-004404 · edgar.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,433 Underlying: Common Stock · 3,958 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.